StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Amgen (AMGN) Says FDA Grants Priority Review For its sBLA For Repatha to Include Data On Reducing Risk Of Cardiovascular Events
July 27, 2017 5:51 PM
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Amgen's ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Amgen (AMGN) Reports Submission of Supplemental Biologics License Application For Prolia (denosumab)
July 31, 2017 9:12 AM
Amgen (AMGN) & Allergan (AGN) Report U.S. FDA Submission of Biosimilar Biologics License Application For ABP 980
July 31, 2017 9:03 AM
Amgen (AMGN) Declares $1.15 Quarterly Dividend; 2.6% Yield
July 28, 2017 4:01 PM
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
July 27, 2017 5:50 PM
